According to the announcement of Chengyi Pharmaceutical, the company achieved operating income of 432 million yuan in the first half of 2026, up 3.63% year on year; net profit to mother was 94.887 million yuan, down 15.61% year on year. The decline in profit was affected by increased share payments, market expenses and reduced investment income. After excluding the impact of share payments, net profit to mother was 124 million yuan, an increase of 10.67% year on year. The 2,000-ton pharmaceutical-grade glucosamine hydrochloride API project has passed GMP on-site inspection and is expected to be put into operation in November; ethyl eicosapentaenoate softgels have been launched, corresponding to the annual design production capacity of 500 million capsules for the softgel production line.

According to the announcement of Chengyi Pharmaceutical, the company achieved operating income of 432 million yuan in the first half of 2026, up 3.63% year on year; net profit to mother was 94.887 million yuan, down 15.61% year on year. The decline in profit was affected by increased share payments, market expenses and reduced investment income. After excluding the impact of share payments, net profit to mother was 124 million yuan, an increase of 10.67% year on year. The 2,000-ton pharmaceutical-grade glucosamine hydrochloride API project has passed GMP on-site inspection and is expected to be put into operation in November; ethyl eicosapentaenoate softgels have been launched, corresponding to the annual design production capacity of 500 million capsules for the softgel production line.